Skip to main content
. Author manuscript; available in PMC: 2015 Apr 1.
Published in final edited form as: Cancer Chemother Pharmacol. 2014 Feb 2;73(4):729–736. doi: 10.1007/s00280-014-2399-7

Table 1.

Plasma Pharmacokinetic Parameters after Intravenous Administration of Docetaxel in Combination with CYP3A4 Inducers & Inhibitors

Docetaxel Docetaxel and
Dexamethasone		 Docetaxel and
Efavirenz		 Docetaxel and
Ketoconazole		 Docetaxel and
Ritonavir
Cmaxa (μg/mL) 18.1 ± 2.2 17.2 ± 3.9 25.5 ± 3.2 23.7 ± 2.1 43.5 ± 3.4
 Fold vs. Control - 0.9 1.4 1.3 2.4
C24hra (μg/mL) 0.009 ± 0.0007 BLQ 0.010 ± 0.003 0.009 ± 0.002 0.040 ± 0.005
 Fold vs. Control - N.R. 1.1 1.0 4.3
AUClast (μg*hr/mL) 10.3 7.6 12.4 31.4 71.0
 Fold vs. Control - 0.7 1.2 3.1 6.9
AUC0-∞ (μg*hr/mL) 10.3 7.7 12.5 31.4 N.R.b
 Fold vs. Control - 0.7 1.2 3.0 N.R.b
Cl (L/hr/kg) 1.93 2.59 1.60 0.64 N.Rb
Terminal T1/2 (hr) 6.4 4.9 4.7 3.5 N.R.b
a

For Cmax and C24hr, individual data is reported (n=3/cohort). For all other pharmacokinetic parameters, the results are from the average concentration-time profile.

b

Not reported due to >50% extrapolation of the AUC due to poor terminal disposition rate constant (λz).

Abbreviations: AUC0-∞, area under the concentration-time curve extrapolated to infinity; BLQ, below limits of quantitation; Cmax, maximum concentration; %C.V., percent coefficient of variation; Min, minimum; Max, maximum; St. Dev., standard deviation; Terminal T1/2, terminal half-life; Tmax, time to maximum concentration